News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ADial Pharmaceuticals Announces Strategic Partnership With Cato BioVentures


11/5/2013 9:54:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHARLOTTESVILLE, Va., Nov. 4, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals (ADial) announced today that it has entered into a strategic partnership with Cato BioVentures. Under the terms of the agreement, Cato BioVentures will invest up to $1.8 million in ADial, and Cato Research, an affiliate of Cato BioVentures, will serve as the preferred contract research organization for ADial's clinical trials of AD04, ADial's drug for the treatment of alcohol addiction in patients with selected genotypes.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES